Aurobindo Pharma’s CuraTeQ Secures Health Canada Approval for Bevacizumab Biosimilar
Fast facts
- Category: Asia
- Language: EN
- Published: 2026-05-01 10:17 UTC
- Sources: The Hindu
The subsidiary CuraTeQ of Aurobindo Pharma received a Notice of Compliance from Health Canada, authorizing its biosimilar version of the cancer drug bevacizumab. The approval opens the Canadian market to the Indian company's oncology portfolio.
Why it matters
- This update can influence the Asia agenda over the next 24-48 hours.
- It is based on 1 source, which helps cross-check key claims quickly.
- Watch follow-up statements and market/public response to assess real impact.